-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70

Benzinga·10/15/2026 13:14:08
语音播报
JP Morgan analyst Joyce Zhou initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Overweight rating and announces Price Target of $70.